ArticleCureus2025
Usefulness and Ease of Use of an Artificial Intelligence Chatbot for Kidney Stone Formers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transforming Urological Care With Artificial Intelligence Chatbots: From Digital Assistants to Clinical Partners.International neurourology journal · 2026Review
- Large language model chatbots for patient education in kidney stones: a scoping review.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Kidney stone formers need to navigate an overwhelming amount of information for acute stone management and stone recurrence prevention. Artificial intelligence (AI) chatbots may be uniquely equipped to support stone formers in this process. UroGPT™ (Dornier Medtech, Wessling, Germany) is an AI chatbot developed to answer kidney stone-related questions and help kidney stone formers manage their care. The aim of this study is to evaluate the perceived usefulness and ease of use of UroGPT™ among kidney stone formers. Methods A pre-survey and a post-survey were designed to assess participants' experiences with their sources of kidney stone-related information before using UroGPT™, and their experiences using UroGPT™, respectively. Results In all, 626 and 260 participants participated in the pre- and post-survey, respectively. Among post-survey participants, 190 (73.08%) strongly agreed that using UroGPT™ makes it easier for them to get the information they need about kidney stones, 183 (70.38%) strongly agreed that they are satisfied with UroGPT™ for improving their understanding of kidney stones, and 218 (83.85%) strongly agreed that they find UroGPT™ easy to use. UroGPT™ achieved a total Net Promoter Score (NPS) of +75.77. Conclusion This study found that UroGPT™ is generally easy to use and useful for kidney stone formers. A high NPS indicates the potential for UroGPT™ to be widely adopted in kidney stone former communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.